| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/40000 | Human,Mouse,Rat |
| Aliases | MPD2; ALS21; VCPDM |
| WB Predicted band size | 95 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human MATR3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于PI3K p110α抗体的参考文献(虚构示例，仅供格式参考)：
---
1. **文献名称**：*Selective inhibition of oncogenic PI3K p110α by monoclonal antibody therapy in breast cancer models*
**作者**：Smith A, et al.
**摘要**：开发了一种高特异性抗p110α单克隆抗体，可选择性抑制乳腺癌细胞中突变型p110α的活性，减少AKT/mTOR通路激活，并在小鼠模型中抑制肿瘤生长。
---
2. **文献名称**：*Characterization of PI3K p110α isoform-specific antibodies for immunohistochemical analysis*
**作者**：Chen L, Wang Y.
**摘要**：系统评估了多种商业化p110α抗体的特异性，发现克隆号XYZ-123在组织切片中表现最优，可有效区分p110α与其他PI3K亚型，适用于癌症患者样本的蛋白表达定量。
---
3. **文献名称**：*Phosphorylation-dependent activation of PI3K p110α revealed by phospho-specific antibodies*
**作者**：Tanaka K, et al.
**摘要**：开发了针对p110α特定磷酸化位点(Serine 1134)的抗体，揭示了该位点磷酸化在生长因子信号转导中的关键作用，为靶向PI3K通路的药物研发提供工具。
---
(注：以上内容为模拟生成，实际文献需通过PubMed/Google Scholar检索关键词如“PI3K p110α antibody”或“PIK3CA antibody”获取。)
The PI3K p110α antibody is a crucial tool for studying the phosphatidylinositol 3-kinase (PI3K) signaling pathway, which regulates cell growth, proliferation, survival, and metabolism. PI3K p110α (encoded by the *PIK3CA* gene) is the catalytic subunit of class IA PI3K, forming a heterodimer with a regulatory subunit (e.g., p85). This isoform is frequently mutated in cancers, with hotspot mutations (e.g., H1047R, E542K, E545K) driving oncogenic signaling via hyperactivation of the AKT/mTOR pathway. Antibodies targeting p110α enable detection of its expression, localization, and post-translational modifications in tissues or cell lines, aiding research into cancer biology, metabolic disorders, and therapeutic resistance.
These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunoprecipitation (IP). Specificity is critical due to structural similarities among PI3K isoforms (p110α, β, γ, δ). Some antibodies distinguish mutant from wild-type p110α, supporting precision oncology studies. Commercial p110α antibodies are often raised against epitopes in the N-terminal adaptor-binding domain or C-terminal catalytic region. Validation typically includes knockout cell lines or siRNA knockdown to confirm target specificity.
Dysregulation of p110α is implicated in tumorigenesis, making it a therapeutic target. Inhibitors like alpelisib (FDA-approved for breast cancer) underscore the clinical relevance of studying p110α. Researchers also use these antibodies to explore feedback mechanisms, isoform-specific functions, and biomarker development in diseases linked to PI3K pathway activation.
×
